SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. operates as a holding company, which engages in the design, development, manufacture, and sale of smart electric vehicles. It offers its products under the brands NIO, ONVO, and FIREFLY. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Shanghai, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community debates the impact of recent delivery updates, with bulls focusing on strong year-over-year growth and the rollout of new models like the ONVO L80, while bears highlight persistent concerns over stock dilution and market manipulation. Investors are closely monitoring price action as they look for a breakout from current levels, though discussions remain divided between those accumulating shares for long-term potential and those frustrated by consistent price suppression.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is facing heightened investor scrutiny ahead of its earnings report, with community sentiment divided between concerns over dilution and cash burn versus long-term optimism driven by the R2 platform rollout and production scaling. Investors are closely monitoring management's commentary on production milestones and capital management strategies, as they weigh near-term volatility against the company's ambitious growth targets.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure following weak engagement and bookings guidance, with market sentiment further soured by ongoing concerns regarding child safety and regulatory scrutiny. While some investors argue that the stock's current valuation is an attractive entry point for long-term growth, others remain skeptical due to persistent net losses and the platform's struggle to balance user safety with expansion.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing a massive, sentiment-driven rally fueled by an exceptionally low float and extreme short interest, leading to intense speculation about a potential gamma squeeze. While retail investors are actively sharing parabolic price targets and comparing the volatility to previous short-squeeze phenomena, market participants are also closely watching the company's recent pivot toward telecommunications infrastructure as a potential long-term catalyst.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is capturing community attention as investors debate its long-term potential ahead of the upcoming XRP Vegas conference, with many speculating that a major partnership announcement will serve as a key catalyst. While some holders are expressing frustration over price volatility and questioning the project's transparency, a strong base of long-term supporters remains focused on the network's payroll infrastructure and upcoming ecosystem integrations as primary drivers for future growth.

Dogelon Mars

Dogelon Mars continues to trend due to persistent community efforts to drive social engagement and high-frequency trading chatter despite significant historical volatility. Investors are actively discussing the potential for long-term growth driven by speculative hype, meme culture, and hopes for major exchange listings.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is facing significant downward pressure following an $80 million stock and warrant offering, fueling intense community debate over dilution and leadership's capital management. Investors are actively scrutinizing the company's reliance on secondary offerings and potential reverse split risks, while many express deep frustration with management's performance despite the underlying technology's potential.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is experiencing heightened volatility and selling pressure as investors rotate capital into other tech leaders, despite strong long-term projections for AI-driven data center demand. The community is actively debating whether this pullback represents a temporary consolidation and a buying opportunity or a structural shift driven by concerns over hyperscaler competition and high valuation expectations.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is currently experiencing significant market volatility driven by a mix of positive development milestones and investor apprehension surrounding a potential reverse stock split. The community is actively debating the company's recent preclinical success and partnership payments versus long-term concerns regarding cash runway, leadership transitions, and dilution.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is trending as investors monitor supply chain tensions following China's critical mineral export controls and the company's role as a domestic producer for defense-related industries. The community is actively debating the stock's volatility and its potential as a strategic play, with heavy discussion surrounding the upcoming earnings report and the impact of institutional accumulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rewriting Fat Itself: Hoth Therapeutics May Be Targeting the Root of Metabolic Disease

Hoth Therapeutics (NASDAQ:HOTH) is stepping into one of the most competitive, and lucrative, arenas in biotech with data that suggests a fundamentally different approach to treating metabolic disease. Rather than simply helping patients lose weight, the company’s latest HT-VA study indicates it may be able to reprogram how the body creates and burns fat at the genetic level.

<ul class="summary-bullets"><li>REPL came under pressure after the FDA issued a second Complete Response Letter for RP1 with nivolumab in anti-PD-1-failed melanoma.</li><li>HOTH declined after a $2 million stock offering, along with attached warrants, raised dilution concerns despite recent pipeline updates.</li><li>ONCO is on a major slide after its reverse stock split, while its pending all-stock acquisition of Realbotix has yet to improve investor sentiment.</li></ul>Shares of Replimune (REPL), Hoth Therapeutics (HOTH), and Onconetix (ONCO) hit fresh 52-week lows on Monday following an FDA setback, a discounted offering, and a reverse split that underscored listing-compliance pressure.&nbsp;On Monday,&nbsp;<a href="https://stocktwits.com/symbol/REPL">REPL</a> fell 64%,&nbsp;<a href="https://stocktwits.com/symbol/HOTH">HOTH</a> slipped 1% and&nbsp;<a href="https://stocktwits.com/symbol/ONCO">ONCO</a> declined 27%, while the Health Care Select Sector SPDR Fund (XLV) rose 0.5%.<h2 class="st-heading-2">Regulatory Setback Pressures REPL Shares Again</h2>Pressure on REPL intensified recently after the U.S. Food and Drug Administration (FDA) issued a second Complete Response Letter (CRL) for its lead drug RP1 in combination with Nivolumab in anti-PD-1-failed melanoma, extending regulatory uncertainty that had already followed an earlier CRL last year.The latest development triggered a wave of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/repl-stock-on-track-to-hit-all-time-lows-here-s-why-this-analyst-slashed-price-target-by-85/cZJFHklRIMD">analyst downgrades</a> across Wall Street. Jefferies said the company faces “a tough road ahead” following the FDA’s response, while BMO Capital said the CRL “lays bare the lack of alignment with the FDA and Replimune” throughout clinical development and warned the revised regulatory pathway may now require additional trials.JPMorgan called the outcome “disappointing,” adding it had previously believed “the totality of the data for RP1 warranted an approval.”&nbsp;<h2 class="st-heading-2">Stock Offering Weighs On HOTH Stock</h2>HOTH declined after the company announced earlier this month a stock offering priced at $0.7 per share, expected to generate about $2 million in gross proceeds before expenses, along with warrants exercisable at $0.85.The financing overshadowed pipeline updates over the past month, when the company reported interim Phase 2 progress for HT-001, a topical therapy to treat skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitor cancer treatments. The trial showed that patients reached the primary efficacy endpoint by the sixth week and demonstrated “strong patient benefit across multiple clinically meaningful measures.”&nbsp;However, shares caught a break in after-hours trading on Monday, jumping over 60%, after preclinical data showed its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-hoth-stock-up-after-hours-today/cZJ8gnKRIuz">HT-VA (GDNF) therapy</a> improved key gene markers linked to fat production and metabolism and outperformed Novo Nordisk's semaglutide on liver-fat regulation signals.<h2 class="st-heading-2">ONCO Slides Despite Realbotix Merger Progress</h2>ONCO shares have remained weak since the company implemented a 1-for-5 reverse stock split, effective March 25, to maintain compliance with Nasdaq’s minimum bid price requirement.The reverse split followed a September equity raise of $12.9 million through Series D preferred stock and warrants, with proceeds used in part to reduce outstanding debt and support working capital following the termination of a previously planned merger with Ocuvex.In February, the company entered into an agreement to acquire Realbotix in an all-stock transaction expected to close in the second half of 2026. Realbotix reported delivering its first Vinci-equipped humanoid robot to Ericsson this month and said the platform enables robots to “recognize returning users, recall previous conversations, and track engagement.” The company expects deliveries of 19 robots across March, April and May as production scales.<h2 class="st-heading-2">How Do Retail Traders Feel About REPL, HOTH, ONCO?</h2>On Stocktwits, retail sentiment for REPL was ‘bearish’ amid ‘extremely high’ message volume, while sentiment for both HOTH and ONCO remained ‘extremely bullish,’ also accompanied by ‘extremely high’ message volume.Over the past year, REPL has fallen 77%, HOTH down 36% and ONCO declining 97%, with all three stocks underperforming the broader XLV ETF, which rose 10% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immunitybio-founder-fda-warning-letter-anktiva-ad-never-aired/cZJpYnYRIHR">ImmunityBio Founder Pushes Back After FDA Warning Letter Over Anktiva Claims — Says Ad 'Never Aired At All'</a>

On Monday alone, REPL plunged 64%, ONCO dropped 27%, and HOTH slipped 1%. (Photo credit: Getty Images)

REPL, HOTH, ONCO Stocks Hit 52-Week Lows: What's Driving The Selloff In These Biotech Plays?

On Monday alone, REPL plunged 64%, ONCO dropped 27%, and HOTH slipped 1%, underperforming the broader XLV healthcare ETF.

Equity

<ul class="summary-bullets"><li>HT-VA outperformed Danish drug Novo Nordisk’s blockbuster semaglutide drug in key gene expression markers tied to liver fat regulation, the company said.</li><li>The company is now looking to advance the drug in additional preclinical validation studies.</li></ul> Shares of Hoth Therapeutics, Inc. (HOTH) jumped 70% after-hours on Monday after data from the company’s preclinical trial evaluating its experimental treatment HT-VA showed significant improvements in key genes responsible for fat production and fat metabolism.The company said that the trial showed statistically significant reduction in genes driving fat production and increased fat metabolism, positioning HT-VA as therapy for metabolic-associated fatty liver disease and obesity.The company is now looking to advance the drug in additional preclinical validation studies and evaluate clinical development pathways for metabolic and liver diseases, while also exploring strategic partnerships and collaborations to accelerate development.<h2 class="st-heading-2">Study Takeaways</h2>HT-VA outperformed Danish drug Novo Nordisk’s (NVO) blockbuster semaglutide drug in key gene expression markers tied to liver fat regulation, the company said, while adding that it also demonstrated broad metabolic impact at the genetic levels beyond just weight reduction."These results demonstrate that GDNF (HT-VA) is not simply reducing fat, but fundamentally reprogramming how the body produces and metabolizes fat at the genetic level. The ability to shut down fat creation while activating fat metabolism differentiates GDNF from existing therapies, including GLP-1 agonists," said CEO Robb Knie.HT-VA is part of Hoth’s efforts to move beyond its core dermatology and oncology pipeline, which includes candidates aimed at treating atopic dermatitis and mast-cell derived cancers.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around HOTH stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user expressed optimism for the rally driving the share price past the $1 mark.<stembedurl>https://www.stocktwits.com/Avi_thind/message/650169883</stembedurl><a href="https://stocktwits.com/symbol/HOTH">HOTH stock</a> has lost 38% of its value over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/syre-stock-marks-best-session-in-about-3-years/cZJ8B3cRIuw">SYRE Stock Marks Best Session In About 3 Years — Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is HOTH Stock Up 70% After-Hours Today?

Hoth Therapeutics said that its preclinical trial evaluating its experimental treatment HT-VA showed significant improvements in key genes responsible for fat production and fat metabolism. 

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down...

Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering PR Newswire NEW YORK, April 2, 2026 NEW...

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering

Hoth Therapeutics Announces $2.0 Million Registered Direct Offering Hoth Therapeutics Announces $2.0 Million Registered Direct Offering PR Newswire NEW YORK, April 1, 2026 NEW YORK, April 1, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH), a clinical-stage biopharmaceutical company...

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA 1 by Week Six

Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in Interim Analysis with Patients Reaching ARIGA 1 by Week Six Hungary Approves Trial Expansion as HT-001 Meets Primary Endpoint in...

Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology

Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology Hoth Therapeutics Announces Issuance of Chinese Patent for Cancer Cell-Targeting Technology PR Newswire NEW...

Hoth Therapeutics Deploys OpenClaw AI Platform to Accelerate Drug Discovery

Hoth Therapeutics Deploys OpenClaw AI Platform to Accelerate Drug Discovery Hoth Therapeutics Deploys OpenClaw AI Platform to Accelerate Drug Discovery PR Newswire NEW YORK, March 26, 2026 NEW YORK...

EXCLUSIVE: Hoth Therapeutics Targets Faster Drug Discovery With New AI Platform

Hoth Therapeutics launches OpenClaw AI platform to speed drug discovery, improve data integration, and boost development efficiency.read more...

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

HOTH
Hoth Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest HOTH News

HOTHHoth Therapeutics Inc